Supplements
Supplement: Current and Emerging Treatment Approaches Addess Unmet Needs in Glaucoma Care
Sustained-release implants and micro- or minimally invasive glaucoma surgeries (MIGS) are emerging therapies that address key unmet needs in glaucoma treatment. By broadening the spectrum of interventions, these therapies allow glaucoma specialists to consider more measured approaches earlier in disease progression, with a view to delay as well as safeguard the possibility of further invasive surgeries. Drs. Herbert Reitsamer, Andrew Tatham, and Iqbal Ike K. Ahmed discuss how patient compliance impacts glaucoma progression, the role of sustained-release drug delivery and MIGS in alleviating patient treatment burden, the use of MIGS in combination with cataract surgery, and how these therapies can be incorporated into the treatment paradigm.
Tags: glaucoma
Latest Articles
Congress Symposium to Highlight Practice Management Issues
Rising into Leadership
Accomplished female ophthalmologists offer advice and encouragement.
Two-Step Procedure Shows Positive Results
Study reveals potentially useful prognostic factors in a large cohort of keratoconus patients.
Programme Committee Provides Backbone of ESCRS Scientific Content
Congress programme reflects commitment to innovation and expertise.
ESCRS IOL Power Calculator Accuracy
All seven formulas are accurate, but two stand out, study finds.
A Second Look at the First IOL Implantation
The traditional hero and villain story might not have a bad guy after all.
MIGS Masterclass to Offer Grand Rounds and Wet Labs in Barcelona
Matching Technologies to Presbyopic Patient Needs
Ever-growing selection of IOLs requires careful screening.
Bringing PROMs into the Intermediate Vision Equation
Quality of life tools need to consider modern treatment options.